EC Number   |
Inhibitors |
Structure |
|---|
   3.5.1.92 | (R)-2,4-dihydroxy-3,3-dimethyl-N-(3-oxo-4-phenylbutyl)butanamide |
i.e. RR6, design, synthesis, and characterization of a novel pantetheine analogue, RR6, that acts as a selective, reversible, and competitive vanin inhibitor at nanomolar concentration. Oral administration of RR6 in rats completely inhibits plasma vanin activity and caused alterations of plasma lipid concentrations upon fasting |
   |
| 3.5.1.92 | (R)-2,4-dihydroxy-3,3-dimethyl-N-(3-oxo-4-phenylbutyl)butanamide |
i.e. RR6 |
|
| 3.5.1.92 | 2,3-bis[(2-hydroxyethyl)thio]-1,4-naphthoquinone |
i.e. NSC 95397, from library of pharmacologically active compounds, LOPAC |
|
| 3.5.1.92 | 2-mercaptoethanol |
reduced vanin-1 activity |
|
| 3.5.1.92 | 2-Nitro-5-thiocyanobenzoate |
0.1 mM, 15 min, 10% residual activity in absence of substrate S-pantetheine-3-pyruvate, 51% residual activity in presence of the substrate S-pantetheine-3-pyruvate |
|
| 3.5.1.92 | 4,4'-dithiodipyridine |
0.01 mM, 15 min, no residual activity in absence of substrate S-pantetheine-3-pyruvate, 13% residual activity in presence of the substrate S-pantetheine-3-pyruvate |
|
| 3.5.1.92 | 4,4'-dithiodipyridine |
competitive |
|
| 3.5.1.92 | 5,5'-dithiobis(2-nitrobenzoate) |
0.1 mM, 15 min, 78% residual activity in absence of substrate S-pantetheine-3-pyruvate, 33% residual activity in presence of the substrate S-pantetheine-3-pyruvate |
|
| 3.5.1.92 | 5-(N,N-Hexamethylene)amiloride |
from library of pharmacologically active compounds, LOPAC |
|
| 3.5.1.92 | 8-cyclopentyl-1,3-dipropylxanthine |
from library of pharmacologically active compounds, LOPAC |
|
